10-Q: Zimmer Biomet Reports Strong Q2 2026 Growth

Zimmer Biomet Holdings, Inc. announced a 4.8% increase in net sales for the second quarter of 2026, driven by acquisitions, favorable currency, and product demand.

Summary

• Zimmer Biomet Holdings, Inc. reported a 4.8% increase in net sales for the three months ended June 30, 2026, reaching $2,177.0 million, and a 7.0% increase for the six months ended June 30, 2026, to $4,263.7 million.
• Net earnings for the second quarter of 2026 were $198.3 million, up from $152.8 million in the prior year period, and for the six-month period, net earnings increased to $436.5 million from $334.9 million.
• The company experienced growth across its product categories, with notable increases in Technology & Data, Bone Cement and Surgical (21.1% for the quarter) and S.E.T. (6.4% for the quarter).
• The Paragon 28 acquisition contributed positively to net sales growth, accounting for 0.7% and 2.3% in the respective periods.
• Operating profit for the quarter was $326.1 million, an increase from $300.0 million in the prior year, with an operating profit margin of 15.0% compared to 14.4%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, with strong revenue growth and improved net earnings, despite some ongoing pricing pressures and increased SG&A expenses.

Positives

• Net sales increased by 4.8% to $2,177.0 million in Q2 2026 and by 7.0% to $4,263.7 million for the first six months of 2026.
• Net earnings rose to $198.3 million in Q2 2026 from $152.8 million in Q2 2025, and to $436.5 million for the first six months of 2026 from $334.9 million.
• The Technology & Data, Bone Cement and Surgical segment saw significant growth of 21.1% in Q2 2026.
• The Paragon 28 acquisition positively impacted net sales by 0.7% in Q2 and 2.3% in the first six months of 2026.
• Favorable foreign currency exchange rates contributed positively to net sales growth.
• Operating profit increased to $326.1 million in Q2 2026, with an improved operating margin of 15.0%.

Negatives

• Selling, general and administrative (SG&A) expenses increased as a percentage of net sales to 41.3% in Q2 2026 from 39.2% in Q2 2025.
• Global selling prices experienced a negative effect of 0.8% in Q2 2026 due to pricing pressure from hospitals and healthcare cost containment efforts.
• Operating profit margins in the Americas segment decreased due to the lower margin contribution from Paragon 28 and higher selling expenses.
• Operating profit and margins in EMEA and Asia Pacific segments decreased due to various factors including hedge-related losses and higher bad debt charges.

Risks

• Continued pricing pressure from local hospitals, health systems, and governmental healthcare cost containment efforts.
• Potential for future impairment charges if estimated cash flows for reporting units decrease.
• Risks associated with integrating acquired businesses and realizing anticipated benefits.
• Potential disruption of management's attention due to integration matters from mergers and acquisitions.
• Breaches or failures of IT systems, including by cyber attack.
• Impact of healthcare reform and cost containment measures on reimbursement levels and potential repayment demands.
• Challenges related to changes in and compliance with governmental laws and regulations, including those from the FDA and other regulators.
• Potential for material impairment of intangible assets, including goodwill.

Future Outlook

For 2026, the company expects year-over-year net sales growth of 3.9% to 4.9%, driven by market growth, new products, acquisitions, and favorable currency, partially offset by go-to-market strategy changes and price declines. Operating profit is expected to increase due to higher net sales, leverage from fixed expenses, tariff refunds, and restructuring savings, though partially offset by inflation and higher interest expense.

Management Comments

• Net sales growth was driven by a combination of our Paragon 28 acquisition, positive effects of changes in foreign currency exchange rates, opportunistic end-of-quarter customer purchases, increased ROSA Robot and bone cement sales, market growth and new product introductions.
• The increase in net earnings in both 2026 periods was primarily due to increased net sales, lower acquisition and integration costs due to significant charges incurred in the 2025 periods related to the Paragon 28 acquisition that did not recur, lower spending on R&D projects and savings from our restructuring programs.
• In the six-month period ended June 30, 2026, we recognized a favorable adjustment of approximately $30 million related to probable U.S. tariff refunds.

Industry Context

StockSavvy.ai notes that Zimmer Biomet's performance aligns with broader trends in the medical device industry, particularly the growth in specialized segments like foot and ankle and the increasing adoption of robotic and digital technologies. The company's strategic acquisitions, such as Paragon 28, demonstrate a focus on consolidating market share in high-growth areas.

Comparison to Industry Standards

• The company's net sales growth of 4.8% in Q2 2026 and 7.0% year-to-date is generally in line with or slightly above the average growth rates reported by large-cap medical device companies, which often range from 3-7% depending on the segment.
• The increase in operating profit margin to 15.0% in Q2 2026 is a positive indicator, though it remains lower than some competitors in highly specialized or less competitive niches within the orthopedic market.
• The company's investment in technology and data, including robotic solutions like ROSA, reflects a broader industry trend towards digital integration and AI in surgical procedures, aiming to improve outcomes and efficiency.

Legal Proceedings

• The company is involved in various legal proceedings including product liability, intellectual property, stockholder matters, tax disputes, commercial disputes, employment matters, whistleblower and qui tam claims, and governmental proceedings and investigations.
• Distributors in China have raised legal claims against the company related to changes in sales and distribution strategies.
• Accrued litigation liabilities were $137.9 million as of June 30, 2026.

Stakeholder Impact

• Shareholders may benefit from increased net earnings and a share repurchase program, though ongoing pricing pressures could impact future profitability.
• Employees may be impacted by restructuring programs, but also by investments in sales force and new technologies.
• Customers (hospitals, health systems) face pricing pressures, while also benefiting from new product introductions and technological advancements.
• Creditors are subject to the company's debt covenants and financial health, which appears stable with available credit facilities.

Next Steps

• Continue to monitor the impact of changes to the go-to-market strategy in the U.S. and other international markets.
• Integrate newly acquired businesses and realize anticipated benefits.
• Continue to manage pricing pressures and SG&A expenses.
• Monitor and adapt to evolving healthcare reform and cost containment measures.
• Continue to invest in new product introductions and technological advancements, including robotics and data analytics.

Key Dates

Recommendation

While the company shows strong revenue and earnings growth, driven by acquisitions and operational improvements, ongoing pricing pressures, increasing SG&A, and the integration risks associated with recent acquisitions warrant a cautious approach. The positive outlook is tempered by these factors, suggesting a 'hold' rating until sustained performance and margin improvement are demonstrated.

Keywords

orthopedic, medical devices, surgical technology, reconstructive products, sports medicine, foot and ankle, robotics, acquisitions